Research Papers:

miR-424 acts as a tumor radiosensitizer by targeting aprataxin in cervical cancer

Xia Wang, Qing Li, Hua Jin, Hua Zou, Wei Xia, Nan Dai, Xiao-Yan Dai, Dong Wang, Cheng-Xiong Xu _ and Yi Qing

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:77508-77515. https://doi.org/10.18632/oncotarget.12716

Metrics: PDF 2626 views  |   HTML 2233 views  |   ?  


Xia Wang1,2,*, Qing Li3,*, Hua Jin4, Hua Zou3, Wei Xia3, Nan Dai3, Xiao-Yan Dai3, Dong Wang3, Cheng-Xiong Xu3, Yi Qing3

1Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China

2Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Chengdu, Sichuan 610041, China

3Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China

4Department of Thoracic Surgery, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China

*These authors have contributed equally to this work

Correspondence to:

Cheng-Xiong Xu, email: [email protected]

Yi Qing, email: [email protected]

Keywords: miR-424, aprataxin, radioresistance, cervical cancer

Received: July 05, 2016    Accepted: October 10, 2016    Published: October 18, 2016


Previous studies have shown that some dysregulated miRNAs are involved in radioresistance of tumor cells. Here, we identified significantly decreased miR-424 expression in radioresistant cervical cancer cells and specimens from cervical cancer patients with radioresistance compared to their radiosensitive parental cells and specimens from radiosensitive patients, respectively. Ectopic expression of miR-424 significantly increased radiation-induced DNA damage, cell apoptosis and G2/M cell cycle arrest in radioresistant cervical cancer cells. Notably, miR-424 agomiR treatment can sensitize radioresistant cervical cancer cells to radiation in a xenograft model. Furthermore, we demonstrated that miR-424 regulated radiosensitivity by directly targeting aprataxin. Taken together, these findings suggest that miR-424 acts as a radiosensitizing miRNA and reveal a new therapeutic strategy for radioresistant cervical cancers.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12716